


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Use of the compounds of the formula I

in which

5



X denotes CH or N,

R¹ denotes H, A, Hal, (CH₂)_nHet, (CH₂)_nAr, cycloalkyl having 3 to 7 C atoms, CF₃, NO₂, CN, C(NH)NOH or OCF₃,

R² denotes (CH₂)_nHet, (CH₂)_nAr, cycloalkyl having 3 to 7 C atoms or CF₃,

R³, R⁴ denote H, (CH₂)_nCO₂R⁵, (CH₂)_nCOHet, (CH₂)_nCON(R⁵)₂,
 (CH₂)_nOOO(CH₂)_nHet, CHO, (CH₂)_nOR⁵, (CH₂)_nHet, (CH₂)_nN(R⁵)₂, CH=N-
 OA, CH₂CH=N-OA, (CH₂)_nNHOA, (CH₂)_nN(R⁵)Het, (CH₂)_nCH=N-Het,
 (CH₂)_nOOOR⁵, (CH₂)_nN(R⁵)CH₂CH₂OR⁵, (CH₂)_nN(R⁵)CH₂CH₂OCF₃,
 (CH₂)_nN(R⁵)C(R⁵)HOOOR⁵, (CH₂)_nN(R⁵)CH₂COHet, (CH₂)_nN(R⁵)CH₂Het,
 (CH₂)_nN(R⁵)CH₂CH₂Het, (CH₂)_nN(R⁵)CH₂CH₂N(R⁵)CH₂OOOR⁵,
 (CH₂)_nN(R⁵)CH₂CH₂OR⁵, (CH₂)_nN(R⁵)CH₂CH₂N(R⁵)₂, CH=CHOOOR⁵,
 CH=CHCH₂NR⁵Het, CH=CHCH₂N(R⁵)₂, CH=CHCH₂OR⁵,
 CH=CHCH₂Het, (CH₂)_nN(R⁵)Ar, (CH₂)_nN(OOR)COOR⁵,
 (CH₂)_nN(CONH₂)OOOR⁵, (CH₂)_nN(CONH₂)CONH₂,
 (CH₂)_nN(CH₂OOOR)COOR⁵, (CH₂)_nN(CH₂CONH₂)OOOR⁵,
 (CH₂)_nN(CH₂CONH₂)CONH₂, (CH₂)_nCHR⁵COR⁵, (CH₂)_nCHR⁵OOOR⁵,
 (CH₂)_nCHR⁵CH₂OR⁵, where in each case one of the radicals R³ or R⁴ has the meaning H,

R⁵ denotes H or A

A denotes straight-chain or branched alkyl or cycloalkyl having 2 to 4 C atoms, having 1 to 10 C atoms, alkenyl having 2 to 10 C atoms, alkoxyalkyl having 2 to 10 C atoms or cycloalkyl having 4 to 7 C atoms, each of which is unsubstituted or substituted by Hal or CN,

Het preferably denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical having 1 to 15 C atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal or a linear radical having 1 to 15 C atoms containing one or two hetero atoms,

Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal, OR^S, OOCR^S, COOR^S, CON(R^S)₂, CN, NO₂, NH₂, NHCOR^S, CF₃ or SO₂CH₃,

n denotes 0, 1, 2, 3, 4 or 5 and

Hal denotes F, Cl, Br or I,

and salts and solvates, enantiomers and racemates thereof for the preparation of a medicament for the treatment and prophylaxis of diseases which can be influenced by the binding of the compounds of the formula I to 5 HT receptors.

2. (Original) Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having a 5-HT receptor-antagonistic action.
3. (Currently Amended) Use of compounds according to Claim 1 ~~or~~ 2 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having a 5-HT_{2A} receptor-antagonistic action.
4. (Currently Amended) Use of compounds of the formula I according to Claim 1 ~~2 or~~ 3 and/or physiologically acceptable salts or solvates thereof for the preparation of a medicament for the prophylaxis and/or treatment of psychoses, neurological disorders, amyotrophic lateral sclerosis, eating disorders, such as bulimia, anorexia nervosa, of premenstrual syndrome and/or for positively influencing obsessive

compulsive disorder (OCD).

5. (Currently Amended) Use of the compounds of the formula I according to ~~one or more of the preceding claims~~ claim 1, in which R¹ denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl.
6. (Currently Amended) Use of the compounds of the formula I according to ~~one or more of the preceding claims~~ claim 1, in which R³ denotes (CH₂)_nCO₂R⁵, (CH₂)_nCO-Het, CHO, CH₂OR⁵, (CH₂)_n-Het, (CH₂)_nN(R⁵)₂ or CH=N-OA, (CH₂)_nN(R⁵)Het, (CH₂)_nN(R⁵)CH₂CH₂OR⁵, (CH₂)_nN(R⁵)CH₂Het, (CH₂)_nN(R⁵)CH₂CH₂Het, (CH₂)_nN(R⁵)CH₂CH₂N(R⁵)₂, CH=CHCH₂NR⁵Het, CH=CHCH₂N(R⁵)₂, CH=CHCH₂OR⁵, CH=CHCH₂Het or (CH₂)_nN(R⁵)Ar.
7. (Currently Amended) Use of the compounds of the formula I according to ~~one or more of the preceding claims~~ claim 1, in which R⁴ denotes H.
8. (Currently Amended) Use of the compounds of the formula I according to ~~one or more of the preceding claims~~ claim 1, in which R² denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl.
9. (Currently Amended) Use of the compounds of the formula I according to ~~one or more of the preceding claims~~ claim 1, in which X has the meaning CH.
10. (Original) Use of the compounds of the formula (a) to (o) according to Claim 1:
[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]- (a)
(4-methylpiperazin-1 -yl)amine

4-{2-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]- (b)
ethyl}morpholine

- 4-{3-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]allyl}morpholine (c)
- 1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]pyrrolidin-3-ol (d)
- 1-[1-(4'-fluorobiphenyl-4-yl)-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine (e)
- 1-[5-(2-fluorophenyl)-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine (f)
- 1-[5-furan-2-yl-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine (g)
- N¹-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]ethane-1,2-diamine (h)
- 2-[[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]amino]ethanol (i)
- [1 -biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(2-methoxyethyl)amine (j)
- 2-[[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]methylamino]ethanol (k)
- 1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]-4-methyl-[1,4]diazepam (l)
- 1-[1-(4'-fluorobiphenyl-4-yl)-5-phenyl-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine (m)
- 1-[5-(2-fluorophenyl)-1-(4-pyrrol-1-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine (n)
- [1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-methyl-(1 -methylpyrrolidin-3-yl)amine (o)

and salts and solvates thereof.